Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Country/Region

Topic

August 25, 2016

Dr. Erlend Grønningen from Trondheim, Norway is a Doctors Without Borders/Médecins Sans Frontières (MSF) supervising medical doctor at Boost Hospital in Lashkar Gah, capital of Afghanistan’s Helmand province. Dr Gronningen arrived in Afghanistan in April, 2016, and primarily focuses on internal medicine, as well as the diagnosis and treatment of tuberculosis (TB). This is his second assignment with MSF, having worked in South Sudan in 2014.

May 17, 2016

There is a book kept under lock and key at all times in the tented HIV and tuberculosis (TB) ward of the Doctors Without Borders/Médecins Sans Frontières (MSF) hospital in Bentiu, South Sudan. It doesn’t look like much—its blue ink has started to fade and its pages emit a strong smell of must, mold, and swamp water.

May 12, 2016

The World Health Organization has just recommended that countries move toward shorter treatment regimens for some people with drug-resistant tuberculosis (DR-TB), including people co-infected with HIV, children, and people with simple MDR-TB who have not been treated before or and have no known resistance to any of the drugs in the regimen. This recommendation comes following results from a number of large observation cohort studies using the shortened regimen.

March 29, 2016

MSF urges Indian Prime Minister not to cave into pressure from EU to accept trade deal that could prevent millions of people from accessing lifesaving medicines

March 23, 2016

Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

December 02, 2015

The 2015 Out of Step report presents the results of a survey of 24 countries conducted by Stop TB Partnership and MSF. Building on the first edition of Out of Step published in 2014, this year’s survey tracked of the latest tuberculosis policies, guidelines, and tools across five areas: diagnosis and drug resistance testing; drug-sensitive TB (DS-TB) treatment regimens; MDR-TB treatment regimens; models of care; and regulatory frameworks.

December 02, 2015

GENEVA/CAPE TOWNDoctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership today released the second edition of the Out of Step report, a 24-country survey of policies and practices used today to guide the diagnosis and treatment of tuberculosis (TB).

October 21, 2015

Traversing the seas off the coast of Papua New Guinea’s Gulf Province can be treacherous. For around five months a year, the South East trade winds—known locally as laura bada—regularly howl at around 30 knots per hour, whipping up huge waves and ensuring many of the small open boats used in these parts remain moored. 

Pages